Caspofungin, the first inhibitor of fungal beta-1,3 glucan synthesis to receive approval by the United States Food and Drug Administration, is effective for the treatment of mucosal and invasive candidiasis and invasive aspergillosis. It is also active in vitro and in animal models against a number of other filamentous and dimorphic endemic fungi and in… (More)


Cite this paper

@article{Deresinski2003Caspofungin, title={Caspofungin.}, author={Stanley C Deresinski and David A Stevens}, journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America}, year={2003}, volume={36 11}, pages={1445-57} }